---
title: "BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296376333.md"
description: "BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions."
datetime: "2026-08-19T15:32:41.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296376333.md)
  - [en](https://longbridge.com/en/news/296376333.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296376333.md)
generator: "portal-rs"
---

# BioMarin to acquire Alesta Therapeutics for $275 million for potential rare bone disease treatment

BioMarin will acquire Alesta Therapeutics for $275 million upfront, bolstering BioMarin's unit focused on rare skeletal conditions.

### Related Stocks

- [BMRN.US](https://longbridge.com/en/quote/BMRN.US.md)

## Related News & Research

- [EVP At BioMarin Pharmaceutical Sells $1.16M Of Stock](https://longbridge.com/en/news/298054481.md)
- [BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics](https://longbridge.com/en/news/297679488.md)
- [Labcorp buys MLM Medical Labs](https://longbridge.com/en/news/298332531.md)
- [BioMarin submits FDA sNDA to expand Voxzogo use to children with hypochondroplasia](https://longbridge.com/en/news/298463433.md)
- [BMRN: Portfolio expansion, robust growth, and pipeline innovation drive long-term outlook](https://longbridge.com/en/news/298619253.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**